Effects of 5-HT 2A Receptor Activation on Oxycodone Demand after Short and Long Access Self-Administration in Male and Female Rats
Carter J. Richardson, Alice J. McQueney, Thomas Stevens, Erik J. Garcia
Psychedelic Medicine January 7, 2026 DOI: 10.1177/28314425251408808
Summary
AI-generated from the abstractIn rats that self-administered oxycodone, the psychedelic compound DOI reduced how much they valued the drug, but the effect depended on dose, sex, and how much prior access to oxycodone they had. In rats with short access, DOI lowered demand by decreasing consumption at low prices and making demand more elastic. In rats with long access, low doses of DOI still reduced demand, but high doses increased it. Most of DOI's effects were blocked by a 5-HT2A receptor antagonist, but this antagonist alone also reduced demand in long-access rats. A 5-HT2C receptor antagonist did not block DOI's effects and sometimes added to them.
Study at a glance
| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Male and female Sprague-Dawley rats |
| Interventions | 2 5-dimethoxy-4-iodoamphetamine (DOI) volinanserin (VOL) SB242084 |
| Dose | 0.1 mg/kg/infusion oxycodone; DOI 0.1 mg/kg (and other doses unspecified in abstract) |
| Key finding | DOI dose- and sex-dependently reduced oxycodone demand in rats, an effect driven mostly by the 5-HT2A receptor, but the receptor mediating these effects depended on the short- or long-access condition. |
Abstract
Introduction: Oxycodone is a necessary analgesic medication but carries abuse potential. There is an urgent need to develop therapeutics to reduce abuse potential. Psychedelic compounds may be a viable option, but the behavioral and pharmacological mechanism of action is undefined. Methods: Male and female Sprague–Dawley rats were implanted with indwelling jugular catheters and allowed to self-administer oxycodone (0.1 mg/kg/infusion). Rats were tested in the low-price twice within-session threshold self-administration procedure to quantify oxycodone reinforcement value before and after Short (ShA) or Long (LgA) access oxycodone self-administration sessions. Rats were pretreated with 2,5-dimethoxy-4-iodoamphetamine (DOI), volinanserin (VOL), and/or SB242084 to determine the therapeutic contribution of the 5-HT 2A R to reduce oxycodone self-administration. Data were analyzed with an exponentiated demand equation to yield the demand parameters demand intensity (Q 0 ) and demand elasticity (α), which summarize consumption across a range of prices. Results: Biological sex did not alter the acquisition of oxycodone self-administration. ShA rats maintained stable oxycodone self-administration. LgA rats escalated their oxycodone intake across training sessions. In ShA male and female rats, DOI dose dependently reduced oxycodone demand by increasing α and decreasing Q 0 . After LgA procedures, the lowest doses of DOI reduced demand in male and female rats, while the highest doses of DOI enhanced oxycodone reinforcement. Most but not all effects of DOI (0.1 mg/kg) were blocked by volinanserin. Interestingly, volinanserin reduced oxycodone demand in LgA male and female rats. SB242084 did not block any effects of DOI on oxycodone demand but showed additive effects with DOI. Conclusion: Regardless of access condition, the hallucinogenic compound, DOI, dose and sex-dependently reduced oxycodone demand by decreasing consumption at near-free prices and/or increasing the elasticity of oxycodone as a reinforcer, an effect driven mostly by the 5-HT 2A R. Notably, the receptor mediating these effects depended on the ShA/LgA condition because selective antagonists differentially blocked the effects. To conclude, while 5-HT 2A R activation maintains its therapeutic efficacy, nonselective phenethylamine hallucinogens that simultaneously activate and block multiple receptors may prove to be beneficial in reducing opioid use disorder by capitalizing on the functional status of various 5-HT 2 Rs.